Rio Tinto stock price edges up as Glencore deal filings land, China approval in spotlight
19 January 2026
2 mins read

Rio Tinto stock price edges up as Glencore deal filings land, China approval in spotlight

London, Jan 19, 2026, 08:26 GMT — Regular session

  • Shares of Rio Tinto Plc rose roughly 0.6% in early London trading
  • Takeover-code disclosures fuel ongoing speculation about a Glencore merger
  • Iron ore prices and demand signals from China continue to sway the market

Rio Tinto Plc (RIO.L) shares inched higher in early London trading Monday, recovering some ground after last week’s buzz around a potential Glencore merger. At 0826 GMT, the stock was trading 0.6% stronger at 6,383 pence. (Investing)

On Monday, a new Takeover Panel disclosure added another layer to the ongoing talks. The Form 8.3 filing—a UK-required document that reveals positions and trades by investors holding 1% or more during an “offer period”—is closely watched by traders looking for hints on which way the wind is blowing. (Stockopedia)

The bigger question: will Beijing greenlight a mega-deal without demanding concessions? Reuters reported that a Rio-Glencore merger might hinge on asset sales to satisfy Chinese regulators, wary of market dominance in copper and iron ore. “China will see this as an opportunity to squeeze out assets,” said Barrenjoey analyst Glyn Lawcock. Mark Kelly, CEO of MKI Global Partners, called it “a long, complicated deal from a regulatory approval perspective,” highlighting sensitivities over Chinalco’s stake in Rio. Both Rio and Glencore declined to comment. (Reuters)

RBC Capital Markets mining analyst Ben Davis noted that investors are leaning toward an all-stock offer, with copper as the key asset. He suggested a 15% to 30% premium over Glencore’s early January share price might be enough to seal the deal and keep BHP from entering a bidding war. (Mining)

Beyond M&A, iron ore remains in focus. The benchmark February contract on the Singapore Exchange slipped 1.64% to $104.6 a tonne by 0355 GMT, marking its lowest since January 2. Renewed concerns over China’s property sector weighed on sentiment. (Business Recorder)

China’s new home prices dropped 0.4% month-on-month in December, while property investment plunged 17.2% in 2025, official figures revealed. These stats are crucial for miners since construction drives steel production, and steelmakers consume most of the world’s seaborne iron ore. (Reuters)

Steel figures released Monday showed a similar trend. China’s crude steel production dropped to 960.81 million tonnes in 2025, marking a seven-year low and a 4.4% decline from 2024, Reuters reported. This came despite exports reaching record highs, highlighting the uneven demand landscape. (Reuters)

Broader risk appetite wobbled. Asian shares slipped after new tariff reports and fresh China data hit the wires, often spiking volatility in cyclicals like miners when sentiment shifts. (Reuters)

Investors holding Rio’s U.S.-listed ADRs will need to watch London trading on Monday, as U.S. markets shut down for Martin Luther King Jr. Day. (New York Stock Exchange)

Yet the deal story has its flipside. Should talks with Glencore stall or regulators demand significant divestments, any merger premium might evaporate quickly; on top of that, softer iron ore prices would intensify the strain.

Rio’s fourth-quarter operations update arrives Jan. 21, with its 2025 full-year results due Feb. 19. Market watchers will zero in on production numbers, cost developments, and any shifts in the company’s M&A commentary. (Riotinto)

Stock Market Today

  • Merck Shares Appear Undervalued Despite Recent Price Gains, DCF Model Shows
    January 19, 2026, 3:44 AM EST. Merck's stock closed at $108.83 with a 7.7% return over 30 days and 15.3% over the past year, lagging peers. A discounted cash flow (DCF) model projecting future free cash flows estimates an intrinsic share value of $201.47, suggesting the stock is approximately 46% undervalued. Merck's recent share strength contrasts with market sentiment shaped by drug pipelines, regulation, and healthcare spending. The stock's price-to-earnings (P/E) ratio reflects investor expectations balancing growth and risk. Merck's five-year return stands at 64.8%, while its valuation metrics indicate potential long-term value despite moderate short-term gains.
RELX stock slips early in London as buyback rolls on and Feb. 12 results loom
Previous Story

RELX stock slips early in London as buyback rolls on and Feb. 12 results loom

Go toTop